BRPI0415966A - combinações compreendendo antagonistas do receptor ampa para tratamento de esquizofrenia - Google Patents

combinações compreendendo antagonistas do receptor ampa para tratamento de esquizofrenia

Info

Publication number
BRPI0415966A
BRPI0415966A BRPI0415966-7A BRPI0415966A BRPI0415966A BR PI0415966 A BRPI0415966 A BR PI0415966A BR PI0415966 A BRPI0415966 A BR PI0415966A BR PI0415966 A BRPI0415966 A BR PI0415966A
Authority
BR
Brazil
Prior art keywords
combinations
treatment
schizophrenia
ampa receptor
receptor antagonists
Prior art date
Application number
BRPI0415966-7A
Other languages
English (en)
Inventor
Kurt Lingenhoehl
Ferenc Martenyi
Silvio Ofner
Mary Ann Karolchyk
Hans O Kalkman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0415966A publication Critical patent/BRPI0415966A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçõES COMPREENDENDO ANTAGONISTAS DO RECEPTOR AMPA PARA TRATAMENTO DE ESQUIZOFRENIA". A presente invenção refere-se a combinações adequadas para o tratamento de distúrbios psiquiátricos/neurológicos, em particular esquizofrenia. As combinações compreendem pelo menos um antagonista do receptor AMPA e pelo menos um composto selecionado do grupo que consiste em (a) drogas antiepilépticas selecionadas de barbituratos e derivados dos mesmos, benzodiazepinas, carboxamidas, hidantoínas, succinimidas, ácido valpróico e outros derivados de ácidos graxos e outras drogas antiepilépticas, (b) antipsicóticos convencionais e (c) antipsicóticos atípicos.
BRPI0415966-7A 2003-10-28 2004-10-27 combinações compreendendo antagonistas do receptor ampa para tratamento de esquizofrenia BRPI0415966A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0325175.8A GB0325175D0 (en) 2003-10-28 2003-10-28 Organic compounds
PCT/EP2004/012150 WO2005049040A1 (en) 2003-10-28 2004-10-27 Combinations comprising ampa receptor antagonists for the treatment of schizophrenia

Publications (1)

Publication Number Publication Date
BRPI0415966A true BRPI0415966A (pt) 2007-01-23

Family

ID=29725529

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415966-7A BRPI0415966A (pt) 2003-10-28 2004-10-27 combinações compreendendo antagonistas do receptor ampa para tratamento de esquizofrenia

Country Status (10)

Country Link
US (1) US20070082873A1 (pt)
EP (1) EP1682157A1 (pt)
JP (1) JP2007509883A (pt)
CN (1) CN1874779A (pt)
AU (1) AU2004290890B2 (pt)
BR (1) BRPI0415966A (pt)
CA (1) CA2541293A1 (pt)
GB (1) GB0325175D0 (pt)
MX (1) MXPA06004780A (pt)
WO (1) WO2005049040A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2079739A2 (en) * 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
JP5788404B2 (ja) 2009-12-11 2015-09-30 アウトイフオンイ トヘラペウトイクス リミテッド イミダゾリジンジオン誘導体
EP2649066B1 (en) 2010-12-06 2015-10-21 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
EP2852588B8 (en) 2012-05-22 2018-01-10 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0424179A3 (en) * 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
US5891871A (en) * 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
CA2269807C (en) * 1996-10-24 2007-04-10 Novartis Ag Substituted aminoalkanephosphonic acids
DK1026950T3 (da) * 1997-10-27 2006-06-26 Univ California Behandling af skizofreni med ampakiner og neuroleptika
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
AU768393B2 (en) * 1999-05-28 2003-12-11 Jeffrey Berlant Compounds and methods for the treatment of post traumatic stress disorder
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
EP1480629A1 (en) * 2002-02-08 2004-12-01 Abbott Laboratories Combination therapy for treatment of schizophrenia
TW200403066A (en) * 2002-04-30 2004-03-01 Novartis Ag New uses of substituted aminoalkanephosphonic acids
DE10332487A1 (de) * 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen
DE10332473A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Epilepsie

Also Published As

Publication number Publication date
US20070082873A1 (en) 2007-04-12
MXPA06004780A (es) 2006-07-03
AU2004290890B2 (en) 2008-10-30
GB0325175D0 (en) 2003-12-03
CA2541293A1 (en) 2005-06-02
WO2005049040A1 (en) 2005-06-02
JP2007509883A (ja) 2007-04-19
EP1682157A1 (en) 2006-07-26
CN1874779A (zh) 2006-12-06
AU2004290890A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
KR102684364B1 (ko) 질환의 치료를 위한 kdm1a 저해제
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
EA200100203A1 (ru) Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов
MXPA05010859A (es) Antagonistas mchr1 heterociclicos.
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
EP1423111A4 (en) FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
WO2002000623A3 (en) Aryl fused substituted 4-oxy-pyridines
EA200600190A1 (ru) Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона
NO20074961L (no) Imidazopyridazinforbindelser
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
SI1716152T1 (sl) Kondenzirane heterociklične spojine in njihova uporaba kot antagonisti metabotropnega receptorja za zdravljenje gastrointestinalnih motenj
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
BR0013311A (pt) Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
CR9622A (es) Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
EA200100516A1 (ru) Производные 3,3-биарилпиперидина и 2,2-биарилморфолина
NO20064238L (no) Imidazolinderivater med CB1 agonistlsk aktivitet
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
MXPA06003374A (es) Derivados de bencimidazolona y quinazolinona como agonistas en receptores semejantes al receptor opioide 1 de humano.
PT1165544E (pt) 1,4-di-hidroindeno¬1,2-c|pirazoles substituidos como inibidores de tirosina-quinase
BRPI0415966A (pt) combinações compreendendo antagonistas do receptor ampa para tratamento de esquizofrenia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.